328 related articles for article (PubMed ID: 16393302)
61. The prevalence of risk factors for gastrointestinal complications and use of gastroprotection among persons hospitalized for cardiovascular disease.
Targownik LE; Al-Mamfud A
Aliment Pharmacol Ther; 2006 Mar; 23(6):743-9. PubMed ID: 16556176
[TBL] [Abstract][Full Text] [Related]
62. Prevention of secondary stroke and transient ischaemic attack with antiplatelet therapy: the role of the primary care physician [corrected].
Kirshner HS
Int J Clin Pract; 2007 Oct; 61(10):1739-48. PubMed ID: 17877660
[TBL] [Abstract][Full Text] [Related]
63. [Antiplatelet drugs and gastrointestinal bleeding: numquam periclum sine periclo vincitur].
Rossini R; Lucà MG; Scuri P; Invernizzi P; Strazzabosco M; Gavazzi A
Ital Heart J Suppl; 2005 Oct; 6(10):621-6. PubMed ID: 16273749
[No Abstract] [Full Text] [Related]
64. Impact of adherence to concomitant gastroprotective therapy on nonsteroidal-related gastroduodenal ulcer complications.
Goldstein JL; Howard KB; Walton SM; McLaughlin TP; Kruzikas DT
Clin Gastroenterol Hepatol; 2006 Nov; 4(11):1337-45. PubMed ID: 17088110
[TBL] [Abstract][Full Text] [Related]
65. Use of antisecretory drugs among consumers of non-steroidal anti-inflammatory drugs in the general population.
Rey E; Elola-Olaso CM; Rodríguez-Artalejo F; Locke GR; Diaz-Rubio M
Aliment Pharmacol Ther; 2006 Dec; 24(11-12):1585-92. PubMed ID: 17206946
[TBL] [Abstract][Full Text] [Related]
66. Aspirin and gastrointestinal toxicity.
Törüner M
Anadolu Kardiyol Derg; 2007 Dec; 7 Suppl 2():27-30. PubMed ID: 18160364
[TBL] [Abstract][Full Text] [Related]
67. Analysis of the upper gastrointestinal tract bleeding prevalence in patients treated due ischaemic heart disease.
Popławski C; Jakubczyk P; Jakubczyk M
Adv Med Sci; 2007; 52():288-93. PubMed ID: 18217435
[TBL] [Abstract][Full Text] [Related]
68. Use of electronic personal health records to identify patients at risk for aspirin-induced gastrointestinal bleeding.
Jackson AN; Kogut S
Consult Pharm; 2013 May; 28(5):313-8. PubMed ID: 23649680
[TBL] [Abstract][Full Text] [Related]
69. Nonsteroidal anti-inflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice.
Moore RA; Derry S; Phillips CJ; McQuay HJ
BMC Musculoskelet Disord; 2006 Oct; 7():79. PubMed ID: 17054784
[TBL] [Abstract][Full Text] [Related]
70. Acid-suppressing drugs and gastroesophageal reflux disease as risk factors for acute pancreatitis--results from a Swedish Case-Control Study.
Sundström A; Blomgren K; Alfredsson L; Wiholm BE
Pharmacoepidemiol Drug Saf; 2006 Mar; 15(3):141-9. PubMed ID: 16200654
[TBL] [Abstract][Full Text] [Related]
71. Proton-pump inhibitors are associated with a reduced risk for bleeding and perforated gastroduodenal ulcers attributable to non-steroidal anti-inflammatory drugs: a nested case-control study.
Vonkeman HE; Fernandes RW; van der Palen J; van Roon EN; van de Laar MA
Arthritis Res Ther; 2007; 9(3):R52. PubMed ID: 17521422
[TBL] [Abstract][Full Text] [Related]
72. Co-prescription of gastro-protectants in hospitalized patients: an analysis of what we do and what we think we do.
Doherty GA; Cannon MD; Lynch KM; Ayoubi KZ; Harewood GC; Patchett SE; Murray FE
J Clin Gastroenterol; 2010 Mar; 44(3):e51-6. PubMed ID: 19609216
[TBL] [Abstract][Full Text] [Related]
73. Proton pump inhibitors and hospital discharge rates for gastrointestinal events in Italy: a national ecological study.
Russo P; Brutti C
Clin Ther; 2007 Apr; 29(4):751-8. PubMed ID: 17617299
[TBL] [Abstract][Full Text] [Related]
74. Concomitant use of buffered and enteric-coated low-dose aspirin products and antisecretory drugs.
Takada M; Fukumoto K; Shibakawa M
J Clin Pharm Ther; 2004 Apr; 29(2):183-7. PubMed ID: 15068408
[TBL] [Abstract][Full Text] [Related]
75. Acid suppressants reduce risk of gastrointestinal bleeding in patients on antithrombotic or anti-inflammatory therapy.
Lin KJ; Hernández-Díaz S; García Rodríguez LA
Gastroenterology; 2011 Jul; 141(1):71-9. PubMed ID: 21458456
[TBL] [Abstract][Full Text] [Related]
76. Predictive and protective factors associated with upper gastrointestinal bleeding after percutaneous coronary intervention: a case-control study.
Chin MW; Yong G; Bulsara MK; Rankin J; Forbes GM
Am J Gastroenterol; 2007 Nov; 102(11):2411-6. PubMed ID: 17850413
[TBL] [Abstract][Full Text] [Related]
77. Gross lower gastrointestinal bleeding in patients on anticoagulant and/or antiplatelet therapy: endoscopic findings, management, and clinical outcomes.
Hashash JG; Shamseddeen W; Skoury A; Aoun N; Barada K
J Clin Gastroenterol; 2009 Jan; 43(1):36-42. PubMed ID: 18698263
[TBL] [Abstract][Full Text] [Related]
78. Effect of clopidogrel on bleeding and transfusions after off-pump coronary artery bypass graft surgery: impact of discontinuation prior to surgery.
Maltais S; Perrault LP; Do QB
Eur J Cardiothorac Surg; 2008 Jul; 34(1):127-31. PubMed ID: 18455412
[TBL] [Abstract][Full Text] [Related]
79. Upper GI risks of NSAIDs and antiplatelet agents: key issues for the cardiologist.
Johnson DA
Rev Cardiovasc Med; 2005; 6 Suppl 4():S15-22. PubMed ID: 17710072
[TBL] [Abstract][Full Text] [Related]
80. Risk of peptic ulcer hospitalizations in users of NSAIDs with gastroprotective cotherapy versus coxibs.
Ray WA; Chung CP; Stein CM; Smalley WE; Hall K; Arbogast PG; Griffin MR
Gastroenterology; 2007 Sep; 133(3):790-8. PubMed ID: 17854591
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
